Key Data From the BMT CTN 1506/MORPHO Trial of Gilteritinib in FLT3-ITD+ AML
June 15th 2023Mark J. Levis, MD, PhD, discusses the takeaways from the phase 3 BMT CTN 1506/MORPHO trial which evaluated maintenance gilteritinib after allogeneic stem cell transplant in patients with FLT3-ITD–positive acute myeloid leukemia.
Read More
Teclistamab With Talquetamab Shows a Manageable Safety Profile in RRMM
June 12th 2023Yael Cohen, MD, discusses the main safety findings from the phase 1/2 RedirecTT-1 trial, which is evaluating the combination of teclistamab-cqyv and talquetamab for the treatment of patients with relapsed/refractory multiple myeloma.
Read More
Gilteritinib as Maintenance Shows Benefit in MRD+ FLT3-Mutant AML Post HCT
June 12th 2023In patients with FLT3-ITD–mutant acute myeloid leukemia and detectable minimal residual disease after hematopoietic stem cell transplant, treatment with gilteritinib elicited a 48% reduction vs patients without detectable MRD.
Read More
Watch and Wait Remains the Standard in Inactive Early-Stage CLL
June 11th 2023A watch-and-wait approach should remain the standard of care, even in the era of targeted therapies, in patients with early-stage chronic lymphocytic leukemia with inactive disease, according to data from the 2023 EHA Congress.
Read More
Investigational BET Inhibitor Achieves Potent Spleen Volume Reduction in Myelofibrosis
June 10th 2023With BMS-986158 plus ruxolitinib or fedratinib treatment in patients with myelofibrosis, reduction in splenic volume was reported among all patients in part 1A and became more robust at week 24.
Read More
Phase 3 PhALLCON Trial of Ponatinib and Reduced-Intensity Chemo Shows Promise in Ph+ ALL
June 9th 2023Findings from the phase 3 PhALLCON trial show that ponatinib plus reduced-intensity chemotherapy could be a new standard of care for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
Read More
Pelabresib Leads to Hematologic Response in Hydroxyurea-Refractory or Intolerant High-Risk ET
June 9th 2023Preliminary findings from arm 4 of the phase 2 MANIFEST trial show hematologic response and symptom improvement with pelabresib in high-risk essential thrombocythemia that is refractory or intolerant to hydroxyurea.
Read More
Daratumumab-Based Maintenance May Improve PFS After Auto-HCT in Relapsed MM
June 9th 2023Treatment with maintenance daratumumab, with or without pomalidomide, led to a median PFS of 28.5 months in patients with relapsed multiple myeloma after undergoing salvage autologous hematopoietic stem cell transplantation.
Read More
Teclistamab Follow-Up Data Yields Consistent Results in Relapsed/Refractory Multiple Myeloma
June 9th 2023At 2-year follow-up, patients with relapsed/refractory multiple myeloma treated with teclistamab achieved a median progression-free survival of 12.5 months with a median duration of response of 24 months.
Read More
Rapid Responses Seen With Daratumumab Combo in RRMM Pretreated With Lenalidomide
June 9th 2023In patients with relapsed/refractory multiple myeloma who were previously treated with lenalidomide, the combination of daratumumab, ixazomib, and dexamethasone led to improved overall response rates.
Read More
Prolonged Reponses Following ASCT and Standard Consolidation/Induction With Daratumumab Maintenance
June 20th 2021Benefit was seen with daratumumab maintenance therapy for patients with newly diagnosed multiple myeloma who received autologous stem cell transplant plus induction and consolidation therapy with bortezomib, thalidomide, and dexamethasone.
Read More
Promising Responses Seen With Intensified Daratumumab Induction in Ultra High–Risk Multiple Myeloma
June 19th 2021Intensified induction therapy with daratumumab plus cyclophosphamide, bortezomib, lenalidomide, and dexamethasone followed by bortezomib-augmented autologous stem cell transplant resulting in deep remissions or patients with ultra¬ high-risk multiple myeloma or primary plasma cell leukemia.
Read More
Without requiring red blood cell transfusions, luspatercept-aamt led to a mean increase in hemoglobin from baseline levels in 77.1% of patients compared with in 0% treated with placebo in patients with non-transfusion–dependent β-thalassemia in the phase 2 BEYOND trial, according to a presentation during the European Hematology Association 2021 Virtual Congress.
Read More